| P2093 | author name string | Paul J Goodnick | |
| P2860 | cites work | Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine | Q31864356 |
| | Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group | Q33178075 |
| | Treatment of Acute Mania With Aripiprazole in an Older Adult With Noted Improvement in Coexisting Parkinson's Disease | Q34769873 |
| | High-dose olanzapine for treatment-refractory schizophrenia | Q42546783 |
| | Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia | Q43503630 |
| | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 |
| | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia | Q43657299 |
| | A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania | Q43689721 |
| | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial | Q43689740 |
| | A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia | Q43845894 |
| | Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 |
| | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia | Q43975240 |
| | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety | Q44045819 |
| | A possible association between high normal and high dose olanzapine and prolongation of the PR interval | Q44048482 |
| | Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial | Q44299951 |
| | QTc prolongation and high-dose olanzapine. | Q44346830 |
| | High-dose olanzapine for treatment-refractory schizophrenia | Q44387669 |
| | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up | Q44640228 |
| | Urinary retention following repeated high-dose quetiapine | Q44811225 |
| | Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study | Q44874572 |
| | Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial | Q44915194 |
| | The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. | Q53902861 |
| | Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. | Q54077757 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 653-668 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Higher than Physician's Desk Reference (US) doses on atypical antipsychotics | |
| P478 | volume | 4 | |